Animal-free innovations in safety assessment of chemicals How can the process of validation, acceptance and use of animal-free innovative approaches to assess the safety of chemicals be facilitated?
Vaccination rate again drops slightly, HPV vaccination rate drops considerably The vaccination rate for vaccines included in the National Immunisation Programme has dropped slightly by about 1 percent.
First issue RIVM Newsletter We have launched the RIVM newsletter. We would like to keep you informed about the developments in public health and the environment in the Netherlands and our institute.
WHO:RIVM Centre for Healthy Living a good practice for other countries According to the World Health Organization (WHO), the RIVM Centre for Healthy Living is a prime example of how the national government has taken up its stewardship role within the health promo
ANSES and RIVM foster collaboration RIVM was delighted to welcome a delegation from ANSES (French Agency for Food, Environmental and Occupational Health & Safety) in Bilthoven on April 10th.
New test has no added value in Lyme disease of the central nervous system Active Lyme disease of the central nervous system cannot be detected with an ELISpot test.
Influenza-like Illness Incidence Is Not Reduced by Influenza Vaccination Influenza vaccination reduces the number of influenza virus infections but not the overall number of illness.
Lyme disease costs EUR 20 million annually The societal costs of Lyme disease have been determined for the Netherlands for the first time. The disease appears to cost nearly EUR 20 million each year.
Moderate flu season Last winter season, the duration and severity of the influenza epidemic was moderate compared to previous years.
Lab tests alone not conclusive for diagnosis of Lyme disease Lyme disease can cause a variety of complaints in patients. Laboratory tests for the disease can support medical practitioners in making a diagnosis but are not necessarily conclusive.